Results showed that CM-treated CD133−/lo CRC cells grew faster and generated larger tumors than CD133−/lo cells with control medium during chemotherapy (5-Fu or OXA) (Fig. 1a, Supplementary Figures S2d–f). This evidence concerns the gene PROM1 and colorectal carcinoma.